VHB937 Study: Effects of VHB937 in people with early Alzheimer's disease
The VHB937 study is looking at a new treatment for people in the early stages of Alzheimer's disease. Researchers want to learn if VHB937 can help with memory and daily activities, and to understand its safety. Participation lasts about 72 weeks, with the option to continue in an extension.
Study highlights
Key information about the VHB937 study
- 50 to 85 years old
- Early Alzheimer's disease
- Reliable study partner available
- Infusion
- Study zone: North Central Florida
Study goal and design
Evaluating VHB937 for memory, daily activities, and brain changes
This study evaluates whether VHB937 is safe and beneficial for people with early Alzheimer's disease. Participants are randomized to receive VHB937 (low dose or high dose) or placebo in a double-blind, parallel-group design over 72 weeks, followed by an extension.
The study assesses effects on memory and other thinking abilities, daily activities, and changes in the brain. Researchers will also measure how VHB937 is processed by the body and how the body responds to it.
Study-related care and support
Infusions, safety monitoring, and cognitive assessments
While contributing to research, participants may receive:
- Study medication via intravenous infusion (VHB937 or placebo)
- Regular safety monitoring (vitals, lab tests, ECG, and adverse event checks)
- Cognitive and functional assessments such as CDR-SB and ADAS-Cog14
- Study partner questionnaires about daily activities (ADCS-ADL)
- Brain-related assessments as defined by the study protocol
Other protocol-defined procedures may apply and are discussed with the study team during screening.
Volunteer journey
A structured research experience over 72 weeks
Express your interest
Start with a short questionnaire and share basic details like age and diagnosis of MCI due to AD or mild AD.
Screening and confirmation
The study team checks eligibility, including cognitive testing and confirmation of Alzheimer's disease biomarkers (CSF or amyloid PET), and verifies a study partner can attend visits.
Begin study treatment
If eligible, you are randomized to receive VHB937 (low or high dose) or placebo via IV infusions. The study is double-blind, so neither you nor the study team knows your assigned group.
Follow-up and extension
Attend scheduled visits over 72 weeks for infusions and assessments, with the option to continue into the extension phase if eligible.
Ready to get involved?Join the VHB937 study.
Contribute to progress, support research, help others, and care for your health.